NextCell Pharma AB (STO:NXTCL)
Sweden
· Delayed Price · Currency is SEK 1.148
-0.012 (-1.03%)
Apr 29, 2026, 5:29 PM CET
NextCell Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2021 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | 2021 - 2017 |
| Operating Revenue | 9.62 | 10.94 | 10.66 | 10.11 | 5.59 | Upgrade
|
| Other Revenue | 0.21 | 0.13 | 0.61 | 3.84 | 0.64 | Upgrade
|
| Revenue | 9.83 | 11.06 | 11.28 | 13.96 | 6.23 | Upgrade
|
| Revenue Growth (YoY) | -11.13% | -1.90% | -19.18% | 124.03% | 39.82% | Upgrade
|
| Cost of Revenue | 8.18 | 9.4 | 15.22 | 11 | 8.72 | Upgrade
|
| Gross Profit | 1.66 | 1.67 | -3.94 | 2.96 | -2.49 | Upgrade
|
| Selling, General & Admin | 38.66 | 34.9 | 38.22 | 43.47 | 31.85 | Upgrade
|
| Other Operating Expenses | -0.04 | 0.14 | 0.04 | 0.04 | 0.22 | Upgrade
|
| Operating Expenses | 41.11 | 37.55 | 39.23 | 43.96 | 32.53 | Upgrade
|
| Operating Income | -39.46 | -35.89 | -43.17 | -41 | -35.02 | Upgrade
|
| Interest Expense | -0 | -0 | -0 | -0 | -0.01 | Upgrade
|
| Interest & Investment Income | 0.67 | 0.75 | 1.21 | 1.19 | 0.48 | Upgrade
|
| Pretax Income | -38.79 | -35.14 | -41.96 | -39.81 | -34.55 | Upgrade
|
| Net Income | -38.79 | -35.14 | -41.96 | -39.81 | -34.55 | Upgrade
|
| Net Income to Common | -38.79 | -35.14 | -41.96 | -39.81 | -34.55 | Upgrade
|
| Shares Outstanding (Basic) | - | 76 | 41 | 34 | 34 | Upgrade
|
| Shares Outstanding (Diluted) | - | 76 | 41 | 34 | 34 | Upgrade
|
| Shares Change (YoY) | - | 87.22% | 18.72% | - | 13.05% | Upgrade
|
| EPS (Basic) | - | -0.46 | -1.03 | -1.16 | -1.01 | Upgrade
|
| EPS (Diluted) | - | -0.46 | -1.03 | -1.16 | -1.01 | Upgrade
|
| Free Cash Flow | -46.57 | -43.05 | -37.86 | -47.92 | -40.9 | Upgrade
|
| Free Cash Flow Per Share | - | -0.56 | -0.93 | -1.39 | -1.19 | Upgrade
|
| Gross Margin | 16.84% | 15.07% | -34.98% | 21.19% | -40.03% | Upgrade
|
| Operating Margin | -401.24% | -324.35% | -382.79% | -293.81% | -562.26% | Upgrade
|
| Profit Margin | -394.49% | -317.62% | -372.04% | -285.28% | -554.72% | Upgrade
|
| Free Cash Flow Margin | -473.62% | -389.04% | -335.70% | -343.41% | -656.63% | Upgrade
|
| EBITDA | -36.96 | -33.37 | -42.2 | -40.55 | -34.57 | Upgrade
|
| EBITDA Margin | - | - | - | -290.60% | - | Upgrade
|
| D&A For EBITDA | 2.49 | 2.52 | 0.97 | 0.45 | 0.46 | Upgrade
|
| EBIT | -39.46 | -35.89 | -43.17 | -41 | -35.02 | Upgrade
|
| EBIT Margin | - | - | - | -293.81% | - | Upgrade
|
| Revenue as Reported | 9.83 | 11.06 | 11.28 | 13.96 | 6.23 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.